Ascendis Pharma A/S (ASND) EPS Estimated At $-0.89; FOCUS GRAPHITE ORDINARY SHARES CAN (FCSMF) Shorts Raised By 210%

April 17, 2018 - By Nellie Frank

Focus Graphite Inc. (OTCMKTS:FCSMF) Logo

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.89 EPS on May, 22.They anticipate $0.06 EPS change or 7.23% from last quarter’s $-0.83 EPS. After having $-1.08 EPS previously, Ascendis Pharma A/S’s analysts see -17.59% EPS growth. The stock increased 6.25% or $3.91 during the last trading session, reaching $66.42. About 157,091 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since April 17, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.

FOCUS GRAPHITE INC ORDINARY SHARES CAN (OTCMKTS:FCSMF) had an increase of 210% in short interest. FCSMF’s SI was 6,200 shares in April as released by FINRA. Its up 210% from 2,000 shares previously. With 104,100 avg volume, 0 days are for FOCUS GRAPHITE INC ORDINARY SHARES CAN (OTCMKTS:FCSMF)’s short sellers to cover FCSMF’s short positions. The stock increased 1.32% or $0.0005 during the last trading session, reaching $0.0385. About 89,000 shares traded. Focus Graphite Inc. (OTCMKTS:FCSMF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Focus Graphite Inc., an exploration stage company, acquires, explores for, and develops mineral properties in Québec, Canada. The company has market cap of $16.66 million. The firm primarily explores for graphite, iron, copper, rare-earth elements, and gold deposits. It currently has negative earnings. The Company’s principal property is the Lac Knife graphite deposit that consists of 57 claims covering an area of 2,986.31 hectares located to the south-southwest of Fermont town, Côte-Nord region of Québec.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.76 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma had 22 analyst reports since September 26, 2016 according to SRatingsIntel. As per Monday, September 11, the company rating was maintained by Wedbush. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Monday, February 26 by Wedbush. The rating was maintained by Wells Fargo on Friday, September 22 with “Buy”. The company was maintained on Thursday, January 25 by Bank of America. The firm has “Buy” rating given on Monday, March 19 by Wedbush. The firm has “Outperform” rating by Wedbush given on Monday, September 26. On Thursday, September 28 the stock rating was maintained by Wedbush with “Buy”. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Tuesday, September 26 by Bank of America. The firm earned “Hold” rating on Friday, September 1 by Leerink Swann. Bank of America maintained Ascendis Pharma A/S (NASDAQ:ASND) on Friday, November 17 with “Buy” rating.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: